智通财经APP讯，白云山(600332.SH)披露2024年年度报告，报告期公司实现营收749.93亿元，同比下降0.69%;归母净利润28.35亿元，同比下降30.09%;扣非净利润23.56亿元，同比下降35.18%;基本每股收益1.744元。公司拟向全体股东每股派发现金红利0.40元(含税)。
集团经营业绩同比下降的主要原因是：(1)报告期内，受有效需求不足、行业加速变革、行业政策变化及市场竞争激烈等因素持续影响，集团主要业务板块的经营业绩同比下滑;(2)报告期内，根据《企业会计准则》的相关规定，公司对一心堂药业长期股权投资计提资产减值准备人民币3.86亿元，从而减少本年度利润总额。
报告期内，药品集采、医保改革等行业政策持续深化，大南药板块进一步加大力度聚集资源，推动重点品种和梯队品种培育，不断优化产品布局，提升品牌影响力;持续深耕开拓市场，加速终端销售网络布局，持续发力电商业务，推动产品动销;着力做优特色原料药，加大国际拓展力度。本报告期内，养阴清肺膏、养阴清肺合剂、氨咖黄敏胶囊、头孢克肟系列(含原料)、蜜炼川贝枇杷膏、清开灵产品系列、蛇胆川贝液、小柴胡颗粒、蛇胆川贝枇杷膏等产品的销售收入实现同比较快增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.